{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:16:09Z","timestamp":1788509769896,"version":"build-2803163510"},"reference-count":57,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Medicine"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Methamphetamine use is an increasingly detrimental public health crisis linked to significant cardiovascular harm, particularly methamphetamine-associated cardiomyopathy (MACM), which impairs left ventricular ejection fraction (LVEF). Despite well-documented cardiotoxic effects of methamphetamine, the impact of the route of administration (ROA) on LVEF remains underexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This review examines how various ROAs of methamphetamine affect LVEF. It aims to inform clinical decision-making and support the development of pragmatic, risk-reduction interventions in addiction medicine and emergency settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a narrative review of peer-reviewed literature, prioritizing studies from the last 15 years while including seminal earlier work as well. Eligible studies examined methamphetamine use with reported LVEF or cardiac outcomes stratified by ROA. We included human and animal studies across diverse settings and excluded editorials, non-cardiac-focused papers, and studies involving exclusively people &lt;18 years or pregnant individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results\/Findings<\/jats:title>\n                    <jats:p>Our review of 57 papers showed that ROA may impact methamphetamine cardiotoxicity. Intravenous use is linked to abrupt hemodynamic stress, including rapid volume shifts, along with embolic risk and severe LVEF decline. Smoking leads to repeated dosing, oxidative stress, production of harmful pyrolytic intermediates and pulmonary vascular injury. Intranasal use causes systemic vasospasm, while oral ingestion results in prolonged exposure and cumulative myocardial stress. However, direct, comparative clinical data on ROA and LVEF remain sparse and confounded by factors such as polysubstance use, homelessness, and underreporting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ROA may significantly modulate the impact of methamphetamine on LVEF. Future larger-scale, longitudinal studies are critical to clarify this relationship and guide targeted interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10815589261483677","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:10:33Z","timestamp":1787307033000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of methamphetamine route of administration on cardiac function"],"prefix":"10.1177","author":[{"given":"Ananya","family":"Narasimhan","sequence":"first","affiliation":[{"name":"Western University of Health Sciences, College of Osteopathic Medicine of the Pacific, USA"},{"name":"Kaweah Delta Healthcare District, Emergency Medicine, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katlin","family":"Wieselthier","sequence":"additional","affiliation":[{"name":"Western University of Health Sciences, College of Osteopathic Medicine of the Pacific, USA"},{"name":"Arrowhead Regional Medical Center, Internal Medicine, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Yip","sequence":"additional","affiliation":[{"name":"Western University of Health Sciences, College of Osteopathic Medicine of the Pacific, USA"},{"name":"University of California, Irvine, Internal Medicine, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gursavan","family":"Khatkar","sequence":"additional","affiliation":[{"name":"Western University of Health Sciences, College of Osteopathic Medicine of the Pacific, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Lyon","sequence":"additional","affiliation":[{"name":"Western University of Health Sciences, College of Osteopathic Medicine of the Pacific, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Hall","sequence":"additional","affiliation":[{"name":"Western University of Health Sciences, College of Osteopathic Medicine of the Pacific, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malaika","family":"Menon","sequence":"additional","affiliation":[{"name":"Western University of Health Sciences, College of Osteopathic Medicine of the Pacific, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Brown","sequence":"additional","affiliation":[{"name":"Western University of Health Sciences, College of Osteopathic Medicine of the Pacific, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Fuchs","sequence":"additional","affiliation":[{"name":"Western University of Health Sciences, College of Osteopathic Medicine of the Pacific, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Reddy PK Chau E Patel SV et al. Characteristics of methamphetamine-associated cardiomyopathy and the impact of methamphetamine use on cardiac dysfunction. Am J Cardiol. 2021;154:86\u201391. https:\/\/doi.org\/10.1016\/j.amjcard.2021.06.001","DOI":"10.1016\/j.amjcard.2021.06.001"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","unstructured":"Solomon SD Anavekar N Skali H et al. CHARM Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112:3738\u20133744. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.561423","DOI":"10.1161\/CIRCULATIONAHA.105.561423"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Kevil CG Goeders NE Woolard MD et al. Methamphetamine use and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2019;39:1739\u20131746. https:\/\/doi.org\/10.1161\/ATVBAHA.119.312461","DOI":"10.1161\/ATVBAHA.119.312461"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"Bozkurt B Colvin M Cook J et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation. 2016;134:e579\u2013e646. https:\/\/doi.org\/10.1161\/CIR.0000000000000455","DOI":"10.1161\/CIR.0000000000000474"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Tobolski J Sawyer DB Song SJ Afari ME. Cardiovascular disease associated with methamphetamine use: a review. Heart Fail Rev. 2022;27:2059\u20132065. https:\/\/doi.org\/10.1007\/s10741-022-10261-7","DOI":"10.1007\/s10741-022-10261-7"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Zhao X Lu J Zhang C et al. Methamphetamine induces cardiomyopathy through GATA4\/NF-\u03baB\/SASP axis\u2013mediated cellular senescence. Toxicol Appl Pharmacol. 2023;466:116457. https:\/\/doi.org\/10.1016\/j.taap.2023.116457","DOI":"10.1016\/j.taap.2023.116457"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Reddy PKV Ng TMH Oh EE et al. Clinical characteristics and management of methamphetamine-associated cardiomyopathy: state-of-the-art review. J Am Heart Assoc. 2020;9:e016704. https:\/\/doi.org\/10.1161\/JAHA.120.016704","DOI":"10.1161\/JAHA.120.016704"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Manja V Nrusimha A Gao Y et al. Methamphetamine-associated heart failure: a systematic review of observational studies. Heart. 2023;109:168\u2013177. https:\/\/doi.org\/10.1136\/heartjnl-2022-321610","DOI":"10.1136\/heartjnl-2022-321610"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Curtis JP Sokol SI Wang Y et al. The association of left ventricular ejection fraction mortality and cause of death in stable outpatients with heart failure. Circulation. 2003;42(4):736\u201342. https:\/\/doi.org\/10.1016\/s0735-1097(03)00789-7","DOI":"10.1016\/S0735-1097(03)00789-7"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Bhatia HS Nishimura M Dickson S et al. Clinical and echocardiographic outcomes in heart failure associated with methamphetamine use and cessation. Heart. 2021;107:741\u2013747. https:\/\/doi.org\/10.1136\/heartjnl-2020-317635","DOI":"10.1136\/heartjnl-2020-317635"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Yeo KK Wijetunga M Ito H et al. The association of methamphetamine use and cardiomyopathy in young patients. Am J Med. 2007;120:165\u2013171. https:\/\/doi.org\/10.1016\/j.amjmed.2006.01.024.","DOI":"10.1016\/j.amjmed.2006.01.024"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Won S Hong RA Shohet RV et al. Methamphetamine-associated cardiomyopathy. Clin Cardiol. 2013;36:737\u2013742. https:\/\/doi.org\/10.1002\/clc.22195.","DOI":"10.1002\/clc.22195"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Chamsi-Pasha MA Sengupta PP Zoghbi WA. Handheld echocardiography: current state and future perspectives. Circulation. 2017;136:2178\u20132188. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.026622.","DOI":"10.1161\/CIRCULATIONAHA.117.026622"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"Neeki MM Kulczycki M Toy J et al. Frequency of methamphetamine use as a major contributor toward the severity of cardiomyopathy in adults \u226450 years. Am J Cardiol. 2016;118:585\u2013589. https:\/\/doi.org\/10.1016\/j.amjcard.2016.05.057","DOI":"10.1016\/j.amjcard.2016.05.057"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","unstructured":"Volkow ND Fowler JS Wang GJ et al. Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. PLoS One. 2010;5:e15269. https:\/\/doi.org\/10.1371\/journal.pone.0015269","DOI":"10.1371\/journal.pone.0015269"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"Gentry WB Ghafoor AU Wessinger WD et al. (+)-Methamphetamine-induced spontaneous behavior in rats depends on route of administration. Pharmacol Biochem Behav. 2004;79:751\u2013760. https:\/\/doi.org\/10.1016\/j.pbb.2004.10.006","DOI":"10.1016\/j.pbb.2004.10.006"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Freeling JL McFadden LM. The emergence of cardiac changes following the self-administration of methamphetamine. Drug Alcohol Depend. 2020;212:108029. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108029","DOI":"10.1016\/j.drugalcdep.2020.108029"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Cruickshank CC Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction. 2009;104:1085\u20131099. https:\/\/doi.org\/10.1111\/j.1360-0443.2009.02564.x.","DOI":"10.1111\/j.1360-0443.2009.02564.x"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","unstructured":"Hassan SF Wearne TA Cornish JL et al. Effects of acute and chronic systemic methamphetamine on respiratory cardiovascular and metabolic function. J Physiol. 2016;594:763\u2013780. https:\/\/doi.org\/10.1113\/JP271257","DOI":"10.1113\/JP271257"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Varner KJ Ogden BA Delcarpio J et al. Cardiovascular responses elicited by binge administration of methamphetamine. J Pharmacol Exp Ther. 2002;301:152\u2013159. https:\/\/doi.org\/10.1124\/jpet.301.1.152.","DOI":"10.1124\/jpet.301.1.152"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","unstructured":"Ito H Yeo KK Wijetunga M et al. A comparison of echocardiographic findings in young adults with cardiomyopathy: with and without methamphetamine abuse. Clin Cardiol. 2009;32:E18\u2013E22. https:\/\/doi.org\/10.1002\/clc.20367","DOI":"10.1002\/clc.20367"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","unstructured":"Pro G Hayes C Montgomery BEE et al. Demographic and geographic shifts in preferred route of methamphetamine administration in the US. Drug Alcohol Depend. 2022;237:109535. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109535","DOI":"10.1016\/j.drugalcdep.2022.109535"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"Han B Compton WM Jones CM et al. Methamphetamine use disorder and overdose deaths among US adults. JAMA Psychiatry. 2021;78:1329\u20131342. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.2588","DOI":"10.1001\/jamapsychiatry.2021.2588"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"McKetin R Quinn B Higgs P et al. Clinical and demographic characteristics of people who smoke versus inject methamphetamine. Drug Alcohol Rev. 2021;40:1249\u20131255. https:\/\/doi.org\/10.1111\/dar.13183","DOI":"10.1111\/dar.13183"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","unstructured":"Harris DS Boxenbaum H Everhart ET et al. Bioavailability of intranasal and smoked methamphetamine. Clin Pharmacol Ther. 2003;74:475\u2013486. https:\/\/doi.org\/10.1016\/j.clpt.2003.08.002","DOI":"10.1016\/j.clpt.2003.08.002"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-9556(25)07478-1"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Schepers RJF Oyler JM Joseph REJr et al. Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration. Clin Chem. 2003;49:121\u2013132. https:\/\/doi.org\/10.1373\/49.1.121","DOI":"10.1373\/49.1.121"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","unstructured":"Hart CL Gunderson EW Perez A et al. Acute physiological and behavioral effects of intranasal methamphetamine. Neuropsychopharmacology. 2008;33:1847\u20131855. https:\/\/doi.org\/10.1038\/sj.npp.1301578","DOI":"10.1038\/sj.npp.1301578"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","unstructured":"Lord KC Shenouda SK McIlwain E et al. Oxidative stress contributes to methamphetamine-induced LV dysfunction. Cardiovasc Res. 2010;87:111\u2013118. https:\/\/doi.org\/10.1093\/cvr\/cvq043","DOI":"10.1093\/cvr\/cvq043"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","unstructured":"Manja V Sandhu ATS Asch S et al. Healthcare utilization and LVEF distribution in methamphetamine-associated HF hospitalizations. Am Heart J. 2024;270:156\u2013160. https:\/\/doi.org\/10.1016\/j.ahj.2023.12.014","DOI":"10.1016\/j.ahj.2023.12.014"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","unstructured":"Ramli FF Rejeki PS Ibrahim N et al. Mechanistic review on toxicity effects of methamphetamine. Int J Med Sci. 2025;22:482\u2013507. https:\/\/doi.org\/10.7150\/ijms.99159","DOI":"10.7150\/ijms.99159"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","unstructured":"Sch\u00fcrer S Klingel K Sandri M et al. Clinical characteristics histopathological features and clinical outcome of methamphetamine-associated cardiomyopathy. JACC Heart Fail. 2017;5:435\u2013445. https:\/\/doi.org\/10.1016\/j.jchf.2017.02.017.","DOI":"10.1016\/j.jchf.2017.02.017"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","unstructured":"Kaye S McKetin R Duflou J et al. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction. 2007;102:1204\u20131211. https:\/\/doi.org\/10.1111\/j.1360-0443.2007.01874.x.","DOI":"10.1111\/j.1360-0443.2007.01874.x"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","unstructured":"Paulus MP Stewart JL. Neurobiology clinical presentation and treatment of methamphetamine use disorder. JAMA Psychiatry. 2020;77:959\u2013966. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.0246","DOI":"10.1001\/jamapsychiatry.2020.0246"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","unstructured":"Islam MN Kuroki H Hongcheng B et al. Cardiac lesions and their reversibility after long-term administration of methamphetamine. Forensic Sci Int. 1995;75:29\u201343. https:\/\/doi.org\/10.1016\/0379-0738(95)01765-b","DOI":"10.1016\/0379-0738(95)01765-B"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","unstructured":"Brecht ML O\u2019Brien A von Mayrhauser C et al. Methamphetamine use behaviors and gender differences. Addict Behav. 2004;29:89\u2013106. https:\/\/doi.org\/10.1016\/s0306-4603(03)00082-0","DOI":"10.1016\/S0306-4603(03)00082-0"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","unstructured":"Rawson RA Gonzales R Obert JL et al. Methamphetamine use among treatment-seeking adolescents and adults: differences in patterns and routes of administration. J Subst Abuse Treat. 2005;29:67\u201374. https:\/\/doi.org\/10.1016\/j.jsat.2005.04.001.","DOI":"10.1016\/j.jsat.2005.04.001"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","unstructured":"Kolluru GK Glawe JD Pardue S et al. Methamphetamine causes cardiovascular dysfunction via hydrogen sulfide depletion. Redox Biol. 2022;57:102480. https:\/\/doi.org\/10.1016\/j.redox.2022.102480","DOI":"10.1016\/j.redox.2022.102480"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","unstructured":"Lee SJ Liu S Blackwill H et al. Cardiomyopathy in acute ischemic stroke with methamphetamine use. J Am Heart Assoc. 2024;13:e033667. https:\/\/doi.org\/10.1161\/JAHA.123.033667","DOI":"10.1161\/JAHA.123.033667"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","unstructured":"Qu YH Leung KP Qiao DF et al. Ion channel remodeling and electrophysiologic consequences of methamphetamine. Biochem Biophys Res Commun. 2014;443:441\u2013446. https:\/\/doi.org\/10.1016\/j.bbrc.2013.11.114","DOI":"10.1016\/j.bbrc.2013.11.114"},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","unstructured":"Gulati M Levy PD Mukherjee D et al. 2021 AHA\/ACC guideline for evaluation and diagnosis of chest pain. J Am Coll Cardiol. 2021;78:e187\u2013e285. https:\/\/doi.org\/10.1016\/j.jacc.2021.07.053","DOI":"10.1016\/j.jacc.2021.07.053"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","unstructured":"Arenas DJ Beltran S Zhou S Goldberg LR. Cocaine cardiomyopathy and heart failure: a systematic review and meta-analysis. Sci Rep. 2020;10:19795. https:\/\/doi.org\/10.1038\/s41598-020-76273-1","DOI":"10.1038\/s41598-020-76273-1"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","unstructured":"Pitts WR Vongpatanasin W Cigarroa JE et al. Effects of intracoronary cocaine on LV function. Circulation. 1998;97:1270\u20131273. https:\/\/doi.org\/10.1161\/01.cir.97.13.1270","DOI":"10.1161\/01.CIR.97.13.1270"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132404"},{"key":"e_1_3_2_46_2","doi-asserted-by":"crossref","unstructured":"Pratama NR Anastasia ES Wardhani NP et al. Clinical outcomes of opioid administration in heart failure. Diabetes Metab Syndr. 2022;16:102636. https:\/\/doi.org\/10.1016\/j.dsx.2022.102636","DOI":"10.1016\/j.dsx.2022.102636"},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","unstructured":"Barletta C Di Natale V Esposito M et al. The rise of fentanyl: molecular aspects and forensic investigations. Int J Mol Sci. 2025;26:444. https:\/\/doi.org\/10.3390\/ijms26020444","DOI":"10.3390\/ijms26020444"},{"key":"e_1_3_2_48_2","doi-asserted-by":"crossref","unstructured":"Tschirhart JN Zhang S. Fentanyl-induced hERG channel block. Mol Pharmacol. 2020;98:508\u2013517. https:\/\/doi.org\/10.1124\/mol.119.119271","DOI":"10.1124\/mol.119.119271"},{"key":"e_1_3_2_49_2","doi-asserted-by":"crossref","unstructured":"Forchuk C Serrato J Scott L. Perceptions of stigma among hospitalized methamphetamine users. Front Public Health. 2024;12:1279477. https:\/\/doi.org\/10.3389\/fpubh.2024.1279477","DOI":"10.3389\/fpubh.2024.1279477"},{"issue":"1","key":"e_1_3_2_50_2","first-page":"1","article-title":"Clinical practice guideline on management of stimulant use disorder","volume":"18","author":"ASAM\/AAAP","year":"2024","unstructured":"ASAM\/AAAP. Clinical practice guideline on management of stimulant use disorder. J Addict Med. 2024;18(Suppl 1):1\u201356.","journal-title":"J Addict Med"},{"key":"e_1_3_2_51_2","doi-asserted-by":"crossref","unstructured":"Hersi M Corace K Hamel C et al. Psychosocial and pharmacologic interventions for methamphetamine use. PLoS One. 2023;18:e0292745. https:\/\/doi.org\/10.1371\/journal.pone.0292745","DOI":"10.1371\/journal.pone.0292745"},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","unstructured":"Rains A Augustine E Miller K et al. Pipe distribution as harm reduction for methamphetamine use. Subst Use Misuse. 2025;60:558\u2013565. https:\/\/doi.org\/10.1080\/10826084.2024.2440379","DOI":"10.1080\/10826084.2024.2440379"},{"key":"e_1_3_2_53_2","doi-asserted-by":"crossref","unstructured":"Cunningham JK Liu LM Muramoto M. Methamphetamine suppression and route of administration. Addiction. 2008;103:1174\u20131186. https:\/\/doi.org\/10.1111\/j.1360-0443.2008.02208.x","DOI":"10.1111\/j.1360-0443.2008.02208.x"},{"key":"e_1_3_2_54_2","doi-asserted-by":"crossref","unstructured":"Voskoboinik A Ihle JF Bloom JE et al. Methamphetamine-associated cardiomyopathy: patterns and predictors of recovery. Intern Med J. 2016;46:723\u2013727. https:\/\/doi.org\/10.1111\/imj.13050","DOI":"10.1111\/imj.13050"},{"key":"e_1_3_2_55_2","doi-asserted-by":"crossref","unstructured":"Farag A Nordt SP Perese J. Methamphetamine poisoning after rectal use. J Emerg Med. 2024;66:e597\u2013e600. https:\/\/doi.org\/10.1016\/j.jemermed.2024.01.004","DOI":"10.1016\/j.jemermed.2024.01.004"},{"issue":"1502","key":"e_1_3_2_56_2","first-page":"55","article-title":"Poor outcomes in methamphetamine-associated cardiomyopathy\u2014a growing health issue in New Zealand","volume":"132","author":"Wang TKM","year":"2019","unstructured":"Wang TKM, Kueh SA, Sutton T, et al. Poor outcomes in methamphetamine-associated cardiomyopathy\u2014a growing health issue in New Zealand. N Z Med J. 2019;132(1502):55\u201366.","journal-title":"N Z Med J"},{"key":"e_1_3_2_57_2","doi-asserted-by":"crossref","unstructured":"Erinoso O Daugherty R Kirk MR et al. Harm reduction strategies in the fentanyl era. Int J Drug Policy. 2024;128:104456. https:\/\/doi.org\/10.1016\/j.drugpo.2024.104456","DOI":"10.1016\/j.drugpo.2024.104456"},{"key":"e_1_3_2_58_2","doi-asserted-by":"crossref","unstructured":"Jones CM Houry D Han B et al. Methamphetamine use in the United States: epidemiologic update. Ann N Y Acad Sci. 2022;1508:3\u201322. https:\/\/doi.org\/10.1111\/nyas.14688","DOI":"10.1111\/nyas.14688"}],"container-title":["Journal of Investigative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589261483677","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10815589261483677","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589261483677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:48:39Z","timestamp":1788508119000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10815589261483677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":57,"alternative-id":["10.1177\/10815589261483677"],"URL":"https:\/\/doi.org\/10.1177\/10815589261483677","relation":{},"ISSN":["1081-5589","1708-8267"],"issn-type":[{"value":"1081-5589","type":"print"},{"value":"1708-8267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"10815589261483677"}}